BioVie announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study of NE3107 in patients with mild to moderate Alzheimer’s disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA. The poster, Metabolic Dysregulation in Probable Alzheimer’s Disease, discusses the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and Alzheimer’s Disease, and details baseline metabolic and inflammation characteristics from the Phase 3 study, including data on the regulation of glycemia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIVI:
- BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association
- BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress